Ionis Pharmaceuticals IONS Increase (Decrease) in Contract with Customer, Asset

Increase (Decrease) in Contract with Customer, Asset at other companies

UL SolutionsULS

$16M-36.0%

Chart IndustriesGTLS

$63.7M-28.4%

GE VernovaGEV

$399M+7.8%

Powell IndustriesPOWL

-$20.31M-189%

GE HealthCare TechnologiesGEHC

$46M+188%

WAT

Waters CorporationWAT

$138M+66.3%

Other financials

Income statement

See full

Revenue$246.1M+87.0%

Gross profit$243.1M+86.8%

Operating income-$117.4M+20.0%

Net income-$92.5M+37.0%

EPS (diluted)-$0.56+39.8%

Balance sheet

See full

Cash & equivalents$173.4M-34.4%

Total debt$691.7M+334%

Total equity$491.4M+3.3%

Total assets$3.4B+22.6%

Cash flow

See full

Operating cash flow-$792.8M-426%

CapEx$21.8M+73.0%

Free cash flow-$814.6M-399%

Valuation

See full

Market cap$12.25B+159%

Enterprise value$12.77B+175%

P/S11.6×+5.0×

Profitability

See full

Gross margin98.4%-0.2pp

Operating margin-33.3%-11.0pp

Net margin-30.9%-10.5pp

FCF margin-77.4%+35.3pp

Returns & leverage

See full

Return on equity-67.6%-20.3pp

Debt / equity1.4×+1.1×

Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerAsset.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's increase (decrease) in contract with customer, asset.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ionis Pharmaceuticals's increase (decrease) in contract with customer, asset?: Ionis Pharmaceuticals (IONS) reported increase (decrease) in contract with customer, asset of $7.63M in Q1 2026.
How has Ionis Pharmaceuticals's increase (decrease) in contract with customer, asset changed year-over-year?: Ionis Pharmaceuticals's increase (decrease) in contract with customer, asset increased by 114.5% year-over-year, from -$52.48M to $7.63M.